Skip to main content
. 2021 May 26;11:319. doi: 10.1038/s41398-021-01444-1

Table 6.

Comparative effects of 2 years’ exposure to CCBs versus other antihypertensive drug classes on the incidence of the first diagnosis of psychiatric, neurodegenerative, and cerebrovascular disorders. All cohorts were matched for age, sex, race, and blood pressure. Numbers in brackets are risk ratios (this study) or odds ratios (prior studies). “Higher” and “lower” indicate results with confidence intervals not overlapping 1.

ICD-10 codes Incidence with CCBs compared to
Diuretics ACEI ARB RAS agents β-blockers
Psychotic disorder F20–29 Similar (1.02) Similar (1.04) Higher (2.23) Lower (0.69)
Affective disorder F30–39 Lower (0.95) Higher (1.05) Higher (1.27) Lower (0.88)
Anxiety disorder F40–48 Higher (1.06) Higher (1.13) Higher (1.19) Lower (0.89)
Sleep disorder F51, G47 Lower (0.79) Higher (1.18) Similar (1.01) Lower (0.97)
Substance abuse disorder F10–F19 Higher (1.04) Lower (0.95) Higher (1.94) Lower (0.86)
Deliriuma,c F05; R40.0, R41.0 Lower (0.81) Higher (1.51) Lower (0.78)
Dementiab,c F01–03; G30, G31.0, G31.2, G31.83 Higher (1.19) Higher (1.24) Similar (0.96)
Movement disorderb,c G20–26 Lower (0.92) Higher (1.21) Lower (0.73)
Cerebrovascular diseaseb,c I60–69 Higher (1.17) Higher (1.34) Lower (0.86)

aData from ref. 19.

bData from ref. 21.

cIn these studies, ACEIs, and ARBs were grouped together as renin-angiotensin system (RAS) agents.